EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieÄquivalenzstudieRandomisierte kontrollierte Studie

Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial

Wei-Jian Mei iD, Xiao-Zhong Wang, Xuan Zhang, Yue-Ming Sun iD, Chun-Kang Yang, Jun-Zhong Lin iD, Zu-Guang Wu, Rui Zhang, Wei Wang iD, Yong Li iD, Ye-Zhong Zhuang, Jian Lei und 28 weitere

Journal of Clinical Oncology · 10.04.2026 · 44 (11) · 970-980

DOI: 10.1200/jco-25-00731 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2026. Verfasst von Wei-Jian Mei und 39 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinica…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Capecitabine, Chemoradiotherapy, Adjuvant, Neoadjuvant Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The neoadjuvant chemoradiotherapy (nCRT) might accentuate surgical complications and toxicity in the treatment of locally advanced rectal cancer (LARC) while neoadjuvant chemotherapy (nCT) alone shows promise as an alternative treatment. However, which patients deserve most from the nCT need further clarify. This trial aimed to assess the non-inferiority of nCT with capecitabine plus oxaliplatin (CAPOX) versus nCRT with capecitabine in LARC with uninvolved mesorectal fascia (MRF). METHODS Patients with LARC within 12 cm from the anal verge and uninvolved MRF were randomly assigned to receive 4 cycles of CAPOX chemotherapy alone (nCT group) or CRT with concurrent Capecitabine (nCRT group). The primary end point is 3-year locoregional recurrence-free survival (LRRFS). Secondary end points, such as 3-year disease-free survival (DFS), 3-year overall survival (OS), and adverse events (AEs), were also reported. RESULTS A total of 663 patients were enrolled and 589 patients received the allocated treatment (nCT, n = 300; nCRT, n = 289). LRRFS was analyzed with a median follow-up of 48 months. 3-year LRRFS was 97.4% (95% CI, 95.5 to 99.3) in the nCRT group and 96.3% (95% CI, 94.0 to 98.6) in the nCT group, resulting in a hazard ratio (HR) of 1.40 (95% CI, 0.53 to 3.68). The nCT and nCRT achieved similar 3-year DFS (89.2% v 87.9%; HR, 0.88 [95% CI, 0.54 to 1.44]) and 3-year OS (95.0% v 94.1%; HR, 0.86 [95% CI, 0.42 to 1.76]). The nCT group showed a lower incidence of grade 2 to 4 long-term AEs (16.0% v 26.3%, P = 0.002) and proctitis (33.6% v 41.7%, P = 0.049) compared with nCRT group. CONCLUSIONS The non-inferiority of nCT was not confirmed with a very low incidence of local recurrence in both group. But nCT offers comparable DFS and OS while mitigating the burden of toxicity as compared to nCRT. These insights shed light on a potential paradigm shift in the treatment for LARC with uninvolved MRF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCapecitabineChemoradiotherapy, AdjuvantNeoadjuvant TherapyRectal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedChemoradiotherapyDisease-Free SurvivalFasciaOxaliplatin

Substanzen

CapecitabineOxaliplatin

Autor:innen und Institutionen

  • Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, PR China.
  • Shantou Central Hospital, Shantou, PR China.
  • The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Kunming, PR China.
  • The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
  • Fujian Medical University Cancer Hospital, Fuzhou, PR China.
  • Department of Gastrointestinal Surgery, Meizhou People's Hospital, Meizhou, PR China.

ORCID-Profile: Wei-Jian Mei, Yue-Ming Sun, Jun-Zhong Lin, Wei Wang, Yong Li, Wen-Liang Li, Zi-Qiang Wang, Xian-Wei Mo, Yuan-Hong Gao, Wei-Wei Xiao, Jing-Hua Tang, Zhen-Hai Lu, Jin-Xin Bei, Jie-Hai Yu, Pei-Rong Ding

Zitieren

APA

Mei, W. J., Wang, X. Z., Zhang, X., Sun, Y. M., Yang, C. K., Lin, J. Z., Wu, Z. G., Zhang, R., Wang, W., Li, Y., Zhuang, Y. Z., Lei, J., Wan, X. B., Ren, Y. K., Cheng, Y., Li, W. L., Wang, Z. Q., Xu, D. B., Mo, X. W., …, & Ding, P. R. (2026). Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial. Journal of Clinical Oncology, 44(11), 970-980. https://doi.org/10.1200/jco-25-00731

Vancouver

Mei WJ, Wang XZ, Zhang X, Sun YM, Yang CK, Lin JZ, et al. Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial. Journal of Clinical Oncology. 2026;44(11):970-980. doi:10.1200/jco-25-00731

BibTeX
@article{Mei2026,
  author = {Mei, Wei-Jian and Wang, Xiao-Zhong and Zhang, Xuan and Sun, Yue-Ming and Yang, Chun-Kang and Lin, Jun-Zhong and Wu, Zu-Guang and Zhang, Rui and Wang, Wei and Li, Yong and Zhuang, Ye-Zhong and Lei, Jian and Wan, Xiang-Bin and Ren, Ying-Kun and Cheng, Yong and Li, Wen-Liang and Wang, Zi-Qiang and Xu, Dong-Bo and Mo, Xian-Wei and Ju, Hai-Xing and Ye, Sheng-Wei and Zhao, Jing-Lin and Zhang, Hong and Gao, Yuan-Hong and Zeng, Zhi-Fan and Xiao, Wei-Wei and Zhang, Xiao-Peng and Li, Yun-Feng and Xie, E and Feng, Yi-Fei and Tang, Jing-Hua and Wu, Xiao-Jun and Chen, Gong and Li, Li-Ren and Lu, Zhen-Hai and Wan, De-Sen and Bei, Jin-Xin and Pan, Zhi-Zhong and Yu, Jie-Hai and Ding, Pei-Rong},
  title = {Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {11},
  pages = {970--980},
  doi = {10.1200/jco-25-00731}
}
Kostenlos starten →